Pfizer (NYSE:PFE – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Pfizer to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, profitability and dividends.
Risk and Volatility
Pfizer has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Pfizer’s competitors have a beta of -0.05, meaning that their average share price is 105% less volatile than the S&P 500.
Institutional & Insider Ownership
68.4% of Pfizer shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.6% of Pfizer shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Pfizer and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pfizer | 2 | 14 | 6 | 0 | 2.18 |
| Pfizer Competitors | 7845 | 13798 | 25820 | 1039 | 2.41 |
Pfizer presently has a consensus price target of $30.32, suggesting a potential upside of 5.12%. As a group, “Pharmaceuticals” companies have a potential upside of 24.61%. Given Pfizer’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Pfizer has less favorable growth aspects than its competitors.
Profitability
This table compares Pfizer and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pfizer | 6.34% | 19.88% | 8.52% |
| Pfizer Competitors | -2,400.61% | -215.91% | -15.58% |
Dividends
Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.0%. Pfizer pays out 245.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 48.0% of their earnings in the form of a dividend. Pfizer has raised its dividend for 16 consecutive years.
Valuation & Earnings
This table compares Pfizer and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Pfizer | $62.58 billion | $7.77 billion | 41.20 |
| Pfizer Competitors | $3.55 billion | $3.17 billion | 559.01 |
Pfizer has higher revenue and earnings than its competitors. Pfizer is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Pfizer beats its competitors on 8 of the 15 factors compared.
About Pfizer
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
